The under investigated facet of the COVID-19 pandemic: Molecular analysis of secondary bacterial infections at a COVID dedicated intensive care unit within a tertiary care center in Lebanon

dc.contributor.authorSleiman, Ahmad
dc.contributor.authorAbdelkhalek, Pascal
dc.contributor.authorDoumat, George
dc.contributor.authorAtallah, Frida
dc.contributor.authorHamadeh, Lama N.
dc.contributor.authorMoussa, Pamela
dc.contributor.authorBou-Akl, Imad J.
dc.contributor.authorDbaibo, Ghassan S.
dc.contributor.authorAraj, George F.
dc.contributor.authorKanj, Souha S.
dc.contributor.authorMahfouz, Rami A.R.
dc.contributor.authorMatar, Ghassan
dc.contributor.authorKanafani, Zeina A.
dc.contributor.authorAbou Fayad, Antoine G.
dc.contributor.departmentExperimental Pathology, Microbiology, and Immunology
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentInternal Medicine
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.departmentCenter for Infectious Diseases Research
dc.contributor.departmentDivision of Infectious Diseases
dc.contributor.departmentPillar Genomics Institute of Precision Medicine
dc.contributor.departmentDivisions of Pulmonary and Critical Care Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:39:16Z
dc.date.available2025-01-24T11:39:16Z
dc.date.issued2023
dc.description.abstractBackground: The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. Secondary bacterial infections are associated with unfavorable outcomes in respiratory viral infections. This study aimed at determining the prevalence of secondary bacterial infections in COVID-19 patients admitted at a tertiary medical center in Lebanon. Methodology: From May till November, 2020, a total of 26 Gram-negative isolates were recovered from 16 patients during the course of their COVID-19 infection with Escherichia coli being the most prevalent. The isolates were assessed for their antimicrobial susceptibility by broth microdilution against 19 antimicrobial agents from different classes. Whole genome sequencing of 13 isolates allowed the mining of antimicrobial resistance (AMR) determinants as well as mobile genetic elements and sequence types (ST). Finally, broth microdilution with three different efflux pump inhibitors [theobromine, conessine and PheArg-β-naphthylamide (PAβN)] was done. Results: Antimicrobial susceptibility testing showed that out of the 26 Gram-negative isolates, 1 (4%) was extensively drug resistant and 14 (54%) were multi-drug resistant (MDR). Whole genome sequencing results revealed a plethora of AMR determinants among the 13 sequenced isolates. Moreover, the 9 Enterobacterales and 4 Pseudomonas aeruginosa sequenced isolates belonged to 9 and 2 different ST, respectively. Using a variety of efflux pump inhibitors we demonstrated that only PAβN had a significant effect when combined with levofloxacin, and the latter regained its activity against two P. aeruginosa isolates. Conclusion: The identification of carbapenem and colistin resistant Gram-negative bacilli causing secondary bacterial infections in critical patients diagnosed with COVID-19 should be of high concern. Additionally, it is crucial to monitor and track AMR, post-COVID pandemic, in order to better understand the effect of this disease on AMR exacerbation. Copyright © 2023 Sleiman, Abdelkhalek, Doumat, Atallah, Hamadeh, Moussa, Bou Akl, Dbaibo, Araj, Kanj, Mahfouz, Matar, Kanafani and Abou Fayad.
dc.identifier.doihttps://doi.org/10.3389/fmed.2023.1001476
dc.identifier.eid2-s2.0-85148362796
dc.identifier.urihttp://hdl.handle.net/10938/29225
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.relation.ispartofFrontiers in Medicine
dc.sourceScopus
dc.subjectCarbapenem resistance
dc.subjectColistin resistance
dc.subjectCovid-19
dc.subjectMcr-1.26
dc.subjectNdm-5
dc.subjectNdm-7
dc.subjectSecondary bacterial infections
dc.subjectAmikacin
dc.subjectAminoglycoside
dc.subjectAzithromycin
dc.subjectAztreonam
dc.subjectCarbapenem
dc.subjectCarbapenem derivative
dc.subjectCefepime
dc.subjectCeftazidime
dc.subjectCeftolozane plus tazobactam
dc.subjectCefuroxime
dc.subjectCiprofloxacin
dc.subjectColistin
dc.subjectCotrimoxazole
dc.subjectErtapenem
dc.subjectFosfomycin
dc.subjectGentamicin
dc.subjectImipenem
dc.subjectLevofloxacin
dc.subjectMeropenem
dc.subjectPiperacillin plus tazobactam
dc.subjectQuinolone derivative
dc.subjectSteroid
dc.subjectTetracycline
dc.subjectTigecycline
dc.subjectAcinetobacter baumannii
dc.subjectAdult
dc.subjectAntibiotic resistance
dc.subjectAntibiotic sensitivity
dc.subjectArticle
dc.subjectBacilli
dc.subjectBacterium isolate
dc.subjectBroth dilution
dc.subjectClinical article
dc.subjectComorbidity
dc.subjectCoronavirus disease 2019
dc.subjectDemographics
dc.subjectDiabetes mellitus
dc.subjectDisease exacerbation
dc.subjectEnterobacter cloacae
dc.subjectEnterobacterales
dc.subjectEscherichia coli
dc.subjectEscherichia coli infection
dc.subjectFemale
dc.subjectGram negative infection
dc.subjectHeart failure
dc.subjectHospital admission
dc.subjectHospitalization
dc.subjectHuman
dc.subjectIntensive care unit
dc.subjectKidney failure
dc.subjectKlebsiella oxytoca
dc.subjectKlebsiella pneumoniae
dc.subjectLebanon
dc.subjectMale
dc.subjectMiddle aged
dc.subjectMobile genetic element
dc.subjectMortality rate
dc.subjectNonhuman
dc.subjectPandemic
dc.subjectPrevalence
dc.subjectProvidencia stuartii
dc.subjectPseudomonas aeruginosa
dc.subjectSecondary infection
dc.subjectSeptic shock
dc.subjectStenotrophomonas maltophilia
dc.subjectTertiary care center
dc.subjectWhole genome sequencing
dc.titleThe under investigated facet of the COVID-19 pandemic: Molecular analysis of secondary bacterial infections at a COVID dedicated intensive care unit within a tertiary care center in Lebanon
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-908.pdf
Size:
338.15 KB
Format:
Adobe Portable Document Format